Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

NCT04875585 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: neoadjuvant therapy with Pembrolizumab/Lenvatinib
PROCEDURE: Surgery
DRUG: Adjuvant Treatment Phase

Sponsor

Medical University Innsbruck

Collaborators

[object Object]